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Summary.-Concentrations of the hypoxic cell radiosensitizer misonidazole (MIS)
and its 0-demethylated metabolite Ro 05-9963 were determined inplasma(orblood),
brain and tumour afterinjection of I g/kg MIS i.p. to control mice or mice pretreated
with 4-6 daily injections of phenobarbitone or phenytoin. Analysis was by high-
performance liquid chromatography (HPLC).
Phenobarbitone and phenytoin did not alter thepeak MIS concentration in plasma,
brain or tumour. However, the apparent elimination half-life (ti) for MIS was
reduced by20-67%, and the area under the curve (AUC) was decreased by23-49% in
plasma, brain and tumour.
The decrease in MIS ti was associated with an initially increased Ro 05-9963
metabolite concentration. However, the AUC for total 2-nitroimidazole (MIS+Ro
05-9963) in plasma, tumour and brain was reduced by20-50%.
Urinary excretion of MIS and its metabolites accounted for 15-42% of the injected
dose, and was unaltered by pretreatment with phenobarbitone or phenytoin.
Tumour/plasma and brain/plasma concentration ratios for MIS, and tumour/
plasma ratios for Ro 05-9963 were very similar, but the brain/tumour ratios for Ro
05-9963 were considerably lower. Tissue/plasma ratios were unaltered by pretreat-
ment with phenobarbitone or phenytoin.
The acute LD50 for MIS was increased from 1-54 to 1-90 g/kg after phenobarbitone
pretreatment and 1-78 g/kg after phenytoin pretreatment. In addition, pretreatment
with either compound shortened the duration of the MIS-induced decrease in body
temperature.
These data suggest that pretreatment with microsomal-enzyme-inducing agents
may reduce the toxicity of MIS without affecting the radiosensitization. The signifi-
cance of these findings for the mechanism of MIS toxicity is also discussed.
many drugs can be altered by the pre-
vious or simultaneous administration of
other agents (Conney, 1967; Morselli et
al., 1974; Grahame-Smith, 1977). Drug
interactions with antineoplastic agents
have been reviewed recently (Warren &
Bender, 1977).
Phenobarbitone and phenytoin are
known to be potent inducers of micro-
somal drug-metabolizing enzymes in
rodents (e.g. Marshall & McLean, 1969;
Gerber & Arnold, 1969) and in man
THE HYPOXIC cell radiosensitizer mison-
idazole (1-(2-nitroimidazol-1-yl)-3-meth-
oxypropan-22-ol; Ro 07-0582, Roche Lab-
oratories; NSC-261037; MIS) is currently
undergoing clinical trials at several radio-
therapy centres. Previous studies have
shown the importance of MIS disposition
kinetics in governing the toxic and thera-
peutic effects (Dische et al., 1977;
Saunders et al., 1978; Workman et al.,
1978a; Brown et al., 1979).
It is well known that the effects of
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(Pirttiaho et al., 1978). Both compounds
and/or other drugs with enzyme-inducing
side-effects are required by many cancer
patients also receiving MIS.
In the present paper we describe an
investigation of the effects of pheno-
barbitone and phenytoin pretreatment on
the pharmacokinetics and toxicity of MIIS
in mice. The study was designed to ask the
following questions:
(1) Does pretreatment with phenobar-
bitone or phenvtoin affect MIS
pharmacokinetics?
(2) Are the interactions likely to alter
the toxic and therapeutic effects of
MIS?
(3) Do the interactions offer any new in-
formation on the pharmacokinetics
of MIS or the mechanisms respon-
sible for its toxicity?
MATERIALS AND METHOD)S
Anin?als
Adult male BALB/c mice wvere obtained
from the breeding colony at NIMR (Mill Hill,
London) and adult male C57BL/lOScSn
(BI1) mice from Olac (Southern) Limited
(Bicester). Except for urinary excretion
studies, mice wvere housed in plastic cages on
sawdust bedding prepared from soft wvhite
woods (Usher Limited, London). Mice were
fed PRD nuts (Labsure Animal Diets, Poole,
Dorset), and allowed water ad lib. Care w%as
taken to avoid contact wvith known micro-
somal-enzyme inducers, such as halogenated
hydrocarbon insecticides and red cedarwvood
saNwdust (Conney, 1967). Mice wN-eighed 20-
30 g.
T'umours
EMT6 Tunmour. The originial EMT6
tumour wvas described by Rockwell et al.
(1972). The subline used in the present work
was the recently re-designated EMT6/Ca/
VJAC line, previously known as, EMT6/V7J/
AC (Twentyman & Bleehen, 1975).
Briefly, the followring procedure wAas used
to produce solid tumours. In vitro cells, taken
from the 2nd-4th in vitro passage since re-
inoval from the previous in vivo growth as a
solid tumour in the flank, wvere harvested by
trypsinization and suspended at 106 cells/ml
in full medium (Eagle's MEM with Earle's
salts, supplemented wvith 20% calf serum; all
reagents from Gibco-Biocult, Paisley, Scot-
land). BALB/c mice wvere inoculated intra-
dermally in the right mid-flank region with
105 cells in 01 ml medium. Tumour volumes
were calculated by the method of Watson
(1976). Cells inoculated on Day 0 produced
solid tumours Awith mean volumes of 100-
130 mm3 on Day 9. Mice wsith tumours in the
volume range 60-180 mm3 wx-ere selected for
the pharmracokinetic experiments.
MC6B Tumour. The origin and history of
the methylcholanthrene-induced sarcoma
MC6B lhas been described by Sikora et al.
(1977). For the present studies the tumour
was used after 8 (B1O/MC 6B/8/0) or 9 (BlO/
MC 6B/9/0) continuous passages in vivo, wvith
no passages in vitro.
The following procedure w-as used to pro-
duce solid tumours. Two tumours (O 10mm
diameter) Awere excised aseptically from donor
mice and minced finelv wvith scissors. The
tumour fragments were placed in 150 ml
Hanks' balanced salt solution containing
0 05%0 trypsin, and agitated on a magnetic
stirrer for 40 min. The mixture Awas then
filtered through cotton gauze, and the filtrate
centrifuged at 3000 g for 10 min. The cell
pellet wvas resuspended in full medium to
neutralize trypsin, centrifuged and resus-
pended in Hanks' solution (HBSS) then
centrifuged again and finally resuspended in
HBSS at 106 cells/ml. The viable yield was
106-107 cells/tumour. BlO mice wvere inocu-
lated as described above for EMT6. Mice
wvere used 9 days after inoculation, -when their
tumours were in the same size range as the
EMT6 tumours.
For both the MC6B and EMT6 tumours,
tumour volumes in mice pretreated with
phenobarbitone or phenytoin were often up
to 10% lower than the saline controls, but
this was usually not significant (P> 0 05).
From our previous studies wve wrould not ex-
pect such small differences to affect tumour
drug concentration (WA'orkman et al., in
preparation).
Drugs
Supplies of MIS and its 0-demethylated
metabolite Ro 05-9963 (1-(2-nitroimidazol-1-
yl)-2, 3-propandiol) wvere provided by Roche
Laboratories (Welwyn Garden City). Phenv-
toin (5.5-diphenylhydantoin, sodium salt) was
obtained from Sigma Chemical Company
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(Poole) and phenobarbitone (sodium salt)
from BDH Laboratories (Poole). Sodium
pentobarbitone was obtained from May &
Baker Limited (Dagenhanm) as a 60 mg/ml
solution for injection (Sagatal).
Drug pretreatnment regimes
Details of the phenobarbitone and pheny-
toin pretreatment regimes are summarized in
Table 1. The pretreatment regimes wAere
similar to those described previously (Mar-
shall & McLean. 1969: Gerber & Arnold,
1969) to induce microsomal drug-metabolizing
enzymes in mice and rats.
Criteria used to assess the effects of the p)retreat-
ment re,gimies
Body weigqht. The body weights of treated
and control mice Aere monitored daily from
the beginning of pretreatrnent to the end of
each experimnent. i.e. Days 3- or 4-9 in-
clusive.
Liver weight. In some experiments the
effect of the pretreatment regimes on liver
weight wNas determined on the same day as
the pharmacokinetic experiment (Day 9).
Liver weight was expressed as a, percentage of
total body wveight.
Pentobarbitone sleeping-tim?e. In some ex-
periments pentobarbitone sleepinig-times
wvere also determined on Day 9. Sodium
pentobarbitone wvas diluted to 6 mg/ml in
HBSS and mice were inijected with 10 ml/kg
i.p., to give 60mg/kg pentobarbitone. Sleep-
ing-time was defined as the time required for
mice to regain the righting reflex (Stevenson
& Turnbull, 1968).
Determiination ofMIS LD50
Experiments were carried out to deteriimine
the effects of the various pretreatment
regimes on the acute LD50 ofMIIS in tumour-
free BALB/c mice. MIS was dissolved in
HBSS at appropriate concentrations. For
MIS doses from 1-117-2-125 g/kg the drug
solution wNNas injected in a fixed volume of
80 ml/kg body wNeight (i.e. 2 ml to a 25g
mouse). At the highest dose of 2 5 g/kg the
volume injected Awas 88-9 ml/kg. MIS was
given as a single i.p. injection on Day 9, and
the mice wA,ere observed for a further 7 days.
Deaths occurred within 3-4 days oftreatment.
The LD50(7d) and 950 confidence limits
were calculated by probit analysis using a
computer programme at the Department of
Radiology, Stanford University School of
Medicine, California, U.S.A., and the com-
puter installation at that university. We
thank Mr E. Parker and Dr J. M. BroNwn for
this analysis.
Pharmxacokinetics of MIS
MIS was prepared for injection as a 25mg/
inl solution in HBSS. The drug -was injected
i.p. at a dose of 1 g/kg (i.e. 40 ml MIS solution
per kg) on Day 9. 1 g/kg is equivalent to
5 mmol/kg.
Tissue and blood or plasm)ia concentrations.-
Twso types of experimental protocol wNere
used:
(1) Cardiac puncture and removal of brain
(and tumiour. At appropriate intervals
after injection, mice Awere bled by
cardiac puncture under diethyl ether
anaesthesia. Plasna was obtained by
centrifugation (2000 g, 10 min) of
heparinized whole blood and stored at
- 20°C. In addition, wAhere appropriate,
the tumour and AN-hole brain were re-
rnoved immediately after cardiac punc-
ture, and these were also stored at
-20'C. Plasma and tissue homogenate
(10-20%0 w/v in distilled wAater) wNere
analysed in duplicate by reversed-
phase high-performance liquid chroma-
TABLE I. Summary of the drug pretreatnient reyinmes
1)I'lg*
Sodiulrn
plhenobarbitonie (i.p.)
Sodiulm
plhenytomi (i.p.)
Amount Tumour I)rutg or Xeluicle
Vol. of (drtg cells injected
l)rtug (coni. aII(l vellicle per dose inoculated, AI\1SJ
vehicle p('I (lose (if any)t BALB/c B1O given
10 rng/ml in saline 10 ml/kg 100 mg/kg Day 0 Day Day Day 9
(0-850 w/v) or '3-7 inc. 2-7 inIc.
Hanks' solutioni
4 ing/ml in saliie 1() ml/kg 40 mg/kg Day 0 D)ay l Day 9
(0 8506o w/v) 4-7 inc.
* Injections betwveen 8 a.m.-12 noon.
t In some experiments BALB/c mice without ttumnouirs were used.
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tography (HPLC) as described pre-
viously (Wl'orkman et al., 1978b) except
that the mobile phase wvas 25%0
methanol/water. The HPLC technique
allows the specific assay of MIS and the
0-demethylated metabolite Ro 05-9963.
(2) Tail bleeding.-In this method serial
blood samples wiere collected, at appro-
priate intervals, from the tail of the
same mouse. Duplicate 5kd samples
wN,ere collected in Microcap pipettes
(Drummond Scientific Company,
U.S.A.) and mixed wNith 45 ,ul distilled
wrater. The diluted whole blood samples
were then stored and analysed by
HPLC. At the final sampling time (8 h)
mice Awere bled by cardiac puncture and
the undiluted heparinized blood samples
stored and analysed in duplicate by
HPLC.
Control studies showed that the con-
centrations of MIS and Ro 05-9963 in
whole blood and plasma were identical.
The two methods therefore gave en-
tirely comparable results.
Urinary excretion. Groups of 5 mice were
contained in a Urimax metabolism cage and
urine was collected for 24 h after MIS injec-
tion. Urine A-as analysed for MIS and Ro
05-9963 and their 3-glucuronidase-hydrolys-
able conjugates, as described previously
(Workman et al., 1978b; White et al., 1979).
Estimation ofpharmnacokineticparam.eters.-
In mice the pharmacokinetics of MIS are
dose dependent (Workman et al., in prepara-
tion). However, for up to 6-8 h after a dose
of 1 g/kg i.p., the elimination of MIS from
l)lood and plasma approximates closely to
first-order kinetics (see Results). The apparent
elimination rate constant (kel) is given by the
slope of the plot of log MIS concentration
against time. The apparent half-life (tl) is
given by ln2/kei. Where the individual
bleeding method w-as used, t, wAas calculated
for individual mice. In experiments a-here
mice were killed at each sampling time, t wA-as
calculated for the w-hole group; this mnethod
wN-as also used to calculate t for the elimina-
tion of MIS from tumour and brain.
The area under the curve (AUC) of plasma,
blood or tissue concentration versus time was
estimated by Simpson's rule. As for t , AUC
was estimated for individual mice or for
groups.
Where peak concentrations are reported,
these are the maximna observed, wN-ith the
earliest sample being at 15 or 30 min. More
detailed absorption studies have shown that
for the 1 g/kg i.p. dose a broad peak is
observed in the blood betw!een 15 and 60 mill.
Tissue/plasma concentration ratios were
calculated by dividing the tissue concentra-
tion by the plasma concentration measured
for the same time in the same nmouse.
Measurement of body tem)perature
In experiments to determine the effects of
phenobarbitone and phenytoin pretreatment
on the decrease in body temperature after
MIS injection, core body temperatures were
measured with a rectal thermistor probe con-
nected to an externally calibrated electric
thermometer (Light Laboratories Limited,
Brighton).
Statistical analysis
Lines of best fit, -with standard errors, were
calculated by least-squares linear-regression
analysis.
Confidence limits and the significance levels
of differences betwreen various treatment
groups were calculated using Student's t
distribution.
RESULTS
Effects of phenobarbitone and phenytoin on
body and liver weight and pentobarbitone
sleeping-time
Body weight. The phenobarbitone pre-
treatment regime caused some initial
weight loss, but this did not exceed 10%
and was normally completely regained by
Day 9. Pretreatment with phenytoini,
saline or HBSS caused little or no weight
loss.
In our BALB/c mice, the approximate
acute LD50 values for single drug doses
were between 150 and 200 mg/kg for
phenobarbitone and 200-240 mg/kg for
phenytoin.
Liver weight and pentobarbitone sleepiny-
time.-In some experiments liver weight
and barbiturate sleeping-time were meas-
ured as indices of the extent of induction
of microsomal drug-metabolizing enzymes
(Marshall & McLean, 1969; Stevenson &
Turnbull, 1968; Gerber & Arnold, 1969).
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TABLE II.---Effects ofpretreatnment withphenobarbitone,phenytoin, or druy vehicle on liver/
body weight ratio and pentobarbitone sleeping-time in tumour-free BALB/c mice
Li-er Nvt/body w t 0
oatmnent iMeanl
Nonie' 4-51
(4.21-481)
Haniks' 4-41
(4-1 1-4-78)
IPl 'einobarbitoine 6-28*
(5-75-6-81)
NonIe 4-10
(:3 86-4.34)
Salillne :3-98
(3-72-424)
I'llellytoill 5.10*
(4-74-5-46)
Untreate(I
control
100
98
139*
100
97
124*
MIear
(5:
(5:
Pentobarbitone
sleeping-time
Untreatedl
a (min) control
73 100
2-94)
61 84
3-69)
26* 36*
(19-33)
87
(80-94)
67t
(56-78)
26*
(21-31)
100
77t
30*
* Phlcnobarbitone or plhenytoii pi-eti-eated grotups sig. (liff. fi om vehicle conitrol (P < 0-001).
t Velicle pretieate(l groups sig. (liff. from no-pretreatment control (0-01 >P > 0-001).
+ 9,50/ confidence limits (n =5-7 mice per gIo'Up).
Some typical results are shown in Table II.
It mav be seen that both phenobarbitone
annd phlenytoin caused a significant in-
crease in liver weight expressed as a per-
centage of total body weight, and a sig-
nificant decrease in pentobarbitone sleep-
ing-time compared to the vehicle controls
(P < 0001). Interestingly, neither saline
nor HBSS had any significant effect on
liver weight compared to untreated con-
trols (P> 0.1) butt both caused a slight
decrease in pentobarbitone sleeping-time
which was reproduicible but not always
statistically significant (Table II).
Effects of phenobarbitone and phenytoin on
MIS pharmacokinetics in normal BALB/c
mtce
The effects of pretreatment with pheno-
barbitone and phenytoin (and the appro-
priate drug vehicles) on the plasma coIn-
centrations of MIS and Ro 05-9963 in
normal BALB/c male mice are demon-
strated in Figs. 1 and 2. Data showing the
effects on various pertinent pharmaco-
kinetic parameters are summarized in
Tables III and IV. Results are presented
for duplicate experiments, to demonstrate
that although the reproducibility was
generally good, some quantitative differ-
ences between experiments were obtained.
Peak MIS concentration. Tables III
and IV show that, in general, peak plasma
MIS concentrations were not significantly
affected by pretreatment with pheno-
barbitone, phenytoin or the drug vehicles
(P > 0 1). The differences in Experiment F
appear to be due to a rather high peak in
the vehicle controls.
Apparent MIS half-life. In most ex-
periments, the apparent t, for MIS in
blood or plasma was somewhat reduced by
pretreatment with drug vehicle, but this
was not always statistically significant
(Figs. IA and 2A and Tables III and IV).
Compared to the vehicle controls the
apparent t was further reduiced by
phenobarbitone and phenytoin, and this
effect was always significant (P < 0.02).
Ro 05-9963 concentration.- Figs. 1 and 2
show that the decrease in MIS t, caused
by the microsomal-enzyme inducers is
associated with a concomitant 1-5-2-fold
increase in the blood or plasma concentra-
tions of the 0-demethylated metabolite
Ro 05-9963 from - 1-4 h. At later times,
the metabolite concentration falls lower
than the controls. In contrast, the Ro
05-9963 concentrations in the vehicle
Pretr
Experimeint A
Experiimcnt B
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FIG. 1.-Concentrations ofMIS (A) and Ro 05-9963 (B) in plasma of control normal BALB/c mice (0)
and those pretreated with phenobarbitone (A) or saline (0) after 1 g/kg MIS i.p. Error bars
indicate 2 x s.e.
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FIG. 2.-Concentrations ofMIS (A) and Ro 05-9963 (B) in blood of control normal BALB/c mice (0)
and those pretreated with phenytoin (A) or saline (0) after 1 g/kg MIS i.p. Error bars indicate
2 x s,e.
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controls were identical to those in the
untreated groups. Similar results were
obtained in several repeat experiments.
Area under the curve. Tables III and IVr
show that the blood or plasma AUCo-sh
for MIS in the vehiele controls was similar
to, or slightly lower than, that for the
untreated groups. In mice pretreated with
phenobarbitone and phenytoin the
AUCO-8h for MIS was considerably lower
than in the vehicle controls.
AUCO8h valuies for the metabolite
Ro 05-9963 were similar for untreated and
vehicle controls, btut rather higher in the
induced mice. In general, the AU(108h for
total 2-nitroimidlazole (MIS+Ro 05-9963)
was similar in the untreated and vehicle
controls, but reduced in the induced nmice.
Effects of phenobarbitone and phenytoin on
MIS pharmacokinetics in BALB/c mnice
beariny the EMT6 tumoutr
In the next series of experiments we
investigated the effects of the microsomal-
enzyme inducers on BALB/c mice bearing
EMT6 tumours. C'oncentrations of MIS
and the metabolite Ro 05-9963 were deter-
mined in tumour, brain and plasma of
mice pretreated with phenobarbitone,
plhenytoin or vehicle alone.
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Phenobarbitone. The effects of pheno-
barbitone are summarized in Figs. 3 and 4
and Table V. Similar data were obtained
in a repeat experiment. Comparison of the
plasma data in Table V with those in
Table III shows that the pharmaco-
kinetics are similar in normal and tumour-
bearing mice, and that phenobarbitone has
the same effect in both.
Comparison oftumour, brainandplasma
levels in control and treated mice yielded
some interesting findings which are dis-
cussed below.
Fig. 3 shows that for both saline and
phenobarbitone pretreated groups, tumour
AIIS concentrations are similar to the
corresponding brain concentrations during
the period 1-6 h after injection. The mean
(+ s.e.) tumour/plasnma ratios in saline and
phenobarbitone pretreated mice were 0 54
+ 009 and 0 50 + 010 respectively. Cor-
responding values for the brain/plasma
ratios were 0 51 + 0404 and 0 48 + 0409 for
saline and phenobarbitone groups respec-
tively. Howvever, the 15min data showed
consistently that the tumour equilibrates
with the plasma more slowly than does the
brain.
As expected from the constant tissue/
plasma ratios, the peak MIS concentra-
100
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Time (h) Time (h)
Ft(. 3. Concentration.s of MIS in plasyna ( , iLg/ml), EMIT6 tuimour (0, ,uglg) and braini (. pug/g)
of BALB/c mice prctreated witlh saline (A) or phenobarbitone (B). Etror bars in(icate typical
2 x s.e. MIS 1 g/kg i.p.
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FIG. 4. Concentrations of Ro 05-996:3 in plasma (0O, yg/ml), EMIT6 tumour (0, ug/g) andl brain (A,
,ug/g) of BALBBc mice pretreate(1 with saline (A) or phenobarbitone (B). Error bars at 2 h indicate
typical 2 x s.e. MIS dose 1 g/kg i.p.
tions and AUCO_6h values for MIS in
tumour and brain were about 50% of the
corresponding plasma values, whereas the
apparent t2 values for MIS in plasma and
corresponding brain and tumour were not
significantly different (P > 0 1, Table V).
In contrast to the above findings for
MIS, dissimilar results were obtained for
the concentrations of the metabolite Ro
05-9963 in tumour and brain. Tumour/
plasma ratios for Ro 05-9963 were similar
to those for MIS; mean values + s.e.
were 0-59+0 04 and 0 49+0 03 for
saline and phenobarbitone groups respec-
tively. The brain/plasma ratios for
the metabolite, on the other hand, were
generally about half those for the parent
drug; mean values ( ± s.e.) were 0 24 + 0 05
and 0 27 +001 for saline and pheno-
barbitone groups respectively. As a conse-
quence, the AUCO_6h for Ro 05-9963 in the
brain was considerably lower than that in
the tumour (Table V).
The effects ofpretreatment with pheno-
barbitone on the kinetic parameters for
brain and tumour (Table V) can be
summarized as follows:
(a) No alteration of the tissue/plasma
nitroimidazole ratios.
(b) No significant effect on peak MIS
concentrations in brain and tumour
(P > 0.1).
(c) Significant reduction ofthe apparent
t, for the elimination of MIS from
brain and tumour (P < 0 001).
(d) Reduction of the AUCO 6h for both
MIS and total 2-nitroimidazole in
brain and tumour.
Phenytoin.-Two experiments were per-
formed on EMT6 tumour-bearing mice,
and the combined data are summarized in
Table VI. Comparison with Table IV
shows that, like phenobarbitone, pheny-
toin has similar effects on normal and
tumour-bearing mice.
Comparison of Tables V and VI reveals
that, in general, the effects of phenytoin
on the pharmacokinetic parameters for
brain and tumour tissues were very similar
to those caused by phenobarbitone. How-
ever, two points are worthy of note.
Firstly, the tissue/plasma MIS ratios in
these experiments were around 0 3, which
is rather lower than in the phenobarbitone
experiments (Table V). Secondly, there is
an indication that phenytoin pretreatment
increased the AUCO 6h for Ro 05-9963 in
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the brain and tumour tissues, an effect not
seen with phenobarbitone (Table VT).
Effects ofphenobarbitone on MISpharmaco-
kinetics in B1.0 mice bearing the MC6B
tumoitr
Two experiments were carr:ied out to
determine the effects of phenobarbitone in
BlO mice bearing the MC6B tumour. The
combined data are summarized in Fig. 5
and Table VII.
The results were very similar to those
obtained for BALB/c mice bearing the
EMT6 tumour. There are, however, 3
interesting differences.
Firstly, the apparent t, values for MIS
elimination are rather longer, ancd the Ro
05-9963 metabolite concentrations cor-
respondingly lower, than those obtained
for BALB/c mice.
Secondly, phenobarbitone pretreatment
caused an increase in AUCO6h for the
metabolite Ro 05-9963 in brain and
tumour tissues. This was seen with pheny-
toin but not phenobarbitone in the
BALB/c strain.
Thirdly, the tissue/plasma ratios with
the BlO strain were higher than those in
BALB/c mice. The mean (± s.e.) ttumour/
A
plasma ratios for MIS in saline and
phenobarbitone pretreated mice were 0 73
+ 0-02 and 0-71 + 0-02 respectively. Cor-
responding values for the brain/plasma
ratios for saline and phenobarbitone
groups were 0-66 + 0 04 and 0 68 + 003
respectively. The mean tumour/plasma
ratios for the metabolite Ro 05-9963 in
saline and phenobarbitone groups were
0-88 + 0 04 and 0 72 + 0-06 respectively.
Clorresponding values for the brain/plasma
ratio were 0 37 + 0O] l and 0-25 + 0 03 for
saline and phenobarbitone groups re-
spectively.
Effects of phenobarbitone and phenytoin on
urinary excretion ofMIS and metabolites
The effects of pretreatment with pheno-
barbitone, phenytoin and saline vehicle on
the 24h urinary excretion of MIS and its
metabolites are summarized in Table VIII.
Of the administered 1 g/kg dose, 15-42%
wA,as recovered as MIS, Ro 05-9963 and
their respective glucuronides. Ro 05-9963
glucuronide was present in lower amounts
than the other nitroimidazoles. There
appear to be no obvious differences in
urinary excretion between the various
groups.
0
0
o in
10
v z 4 6
Time (h) Tinme (hi)
FIG. 5. Concentrations of NITS (A) andl Ro 05-996:3 (B) in bloo(d of B1O mice (with 1IC6B tumoturs)
pretreatedI witlh saline (O) or phenobarbitone (0). Er.ror bars indlicate 2 x s.e. MIS (lose I g/kg i.p.
345S
c
E
V
c 5
IVU-
. ~~~~~~~~~~~~~~~~~~~~~~~~~I n 9 1346
C
£ t
'rl
P. WORKMAN
- u-
t IL-,
-4- :
0 -,
E-.
-
1.1-.
C.l
0 --%, =
:4 =.- 1-:-
jn. =
c
.r- .c
--j
oe',
'7-
~t D H-1
C C~
zc
£
I;~~I-
tO - t
1Qc3Cr X > c
, _
C)
b I
£ ooz-:
^.lo
-.,ICZ _
IO ic4 r- Foo
5 t- - OC
S S
z
V
C
C
. .L.
CfC
S .LCZ
C
S
S
C -
COD
IZI)
kDRUG INTERACTIONS WITH MISONIDAZOLE
TABLE VIII. Fffect of various pretreatments on urinary excretion in
after 1 g/kg MIS
0° Administered( dose excrete(l in 24h urine*
BALIB/c mice
l're-
treatment
None
Salinie
Phlenobarb.
Phenvtoin
Free
12, 8
14, 12
12, 11, 4
9, 7
Ails
Glutcur-
6, 5
12, 6
10, 6, 2
7, 4
Total
18, 1:3
26, 18
22, 17, 8
16, 11.
Ho 05-9963
Glucur-
Free onicle
12, 9
11, 1(
16, 16, 7
12, x
0-2, 1
5, 1
4, 1, 0-1
2, 1
Total
12, 10
16, 11
20, 17, 7
14, 9
MlIS
+
Ro 05-996:3
+
Glucur -
oni'les
30, 23
42, 29
42, 34, 15
30, 20
* D)ata for 2-3 independent determinatiOlls.
Effects of phenobarbitone and phenytoin on
MIS-induced temperature loss
Little change in body temperature was
seen when BALB/c mice pretreated with
saline, phenobarbitone or phenytoin were
injected with 40 ml/kg HBSS (Fig. 6). Also,
the temperature profiles were identical to
those for mice receiving neither pretreat-
ment nor HBSS (data not shown). In
contrast, all 3 pretreated groups showed a
marked decrease in temperature after
I g/kg MIS. However, compared to the
saline group, the phenobarbitone and
phenytoin groups exhibited a slightly
smaller decrease, and a much quicker
return to normal temperature. Similar
results were obtained in several repeat
experiments.
40
32
e28
E 24-
16
-1 0 1 2 3
4 5 6 7 8 9 10 11 12
t
Injection Time (h)
Fie. 6. Effect of various pretreatments oni
bo(dy temperatuire of normal BALB/c mi(ce
-with time after injectioni of Hanks' soltution
(openi symbols) or 1 g/kg MITS (closed
symbols). Aftei pretreatment Nwith saliine
(0, *) plienytoin (A, A) or phenobarbi-
toe (L ). V-- , ambieint tempera-
ture.
Effect of phenobarbitone and phenytoin on
MIS acute LD50
Two separate experiments were carried
out, to investigate the effect of pretreat-
mnent with phenobarbitone, phenytoin and
the saline vehicle on the acute LD50(7d) of
MIS in BALB/c males. Similar results
were obtained in the two experiments, and
the analysis of the combined data is
summarized in Table IX. It may be seen
that whereas the saline vehicle was with-
out effect (P> 1), both phenobarbitone
and phenytoin caused the LD50 to be sig-
nificantlv increased (P < 0 001).
DISCUSSION
In the present paper, we have shown
that pretreatment of mice with pheno-
barbitone or phenytoin profoundly affects
TABLE IX. Acute LD50(7d) for MIIS in
BALB/c male mice after various pre-
treatments
Pretreatment
None
Saline
Plhenobarbitorne
Phenytoinl
LD50(7d)
(950' confidence
li-nits)
(g/kg)
1-58 (1-50-1 65)
1-54 (1-48-1-60)t
1.90 (1.77-20:3)*
1-78 (1-71-1-85)*
10-11 different doses of .1IS 18 e-e used for each
pretreatmerit grotup, ancl 5-1 0 mice Xvere tused at
eacli dose.
t Not sig. (liff. from untreated controls (P > 0- 1).
* Sig. (liff. from saline control (I < 0-001).
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the pharmacokinetics of the hypoxic cell
radiosensitizer MIS. Pretreatment with
these agents shortened the apparent t, for
MIS elimination from blood or plasma by
35-600/, and this was associated with a
concomitant 1P5 to 2-fold increase in the
circulating concentrations of the 0-de-
methylated metabolite Ro 05-9963. Both
phenobarbitone and phenytoin are known
potent inducers in vivo of hepatic micro-
somal drug-metabolizing enzymes, par-
ticularly the mixed-function oxidases
which catalyse, among many other reac-
tions, the 0-demethylation of xenobiotics
(Conney, 1967; Parke, 1968). We also
observed that pretreatment with pheno-
barbitone or phenytoin caused the liver/
body weight ratio to be increased, and
barbiturate sleeping-time to be decreased.
These are among the classical effects of
agents which elevate microsomal mixed-
function oxidase activities in vivo (Mar-
shall & McLean, 1969; Stevenson &
Turnbull, 1968; Gerber & Arnold, 1969).
The preceding data therefore strongly
suggest that the reduced MIS ti after pre-
treatment with phenobarbitone or pheny-
toin is due to the increased metabolism of
MIS to Ro 05-9963 by hepatic microsomal
mixed-function oxidases.
Previous studies at the same drug dose
(1 g/kg) have shown that the t. of MIS is
prolonged after bilateral kidney ligation
(Brown et al., 1979). Taken together
with the present data, it can be seen that
the MIIS t, at this dose is dependent upon
both metabolism and urinary excretion. It
is interesting to note, however, that the
urinary excretion ofMIS, Ro 05-9963, and
their respective glucuronides, was not
affected by phenobarbitone or phenytoin.
Urinary excretion of these compounds
accounted for only 15-420% ofthe adminis-
tered dose (1 g/kg), and this was similar to
the value reported by Flockhart et al.
(1978a) for normal mice given 100 mg/kg.
It is apparent that changes in MIS t, after
enzyme induction are not reflected in the
urinary excretion profile. This may be due
to the involvement of other metabolic
pathways which may not be rate-limiting
with respect to the systemic elimination
ofMIS.
We have seen that MIS pharmaco-
kinetics are similar in normal and EMT6
tumour-bearing BALB/c mice. AMoreover,
the MIS t. was decreased after enzyme
induction both in BALB/c mice with
EMT6 tumours and Bi1 mice with MC6B
tumours. This is of interest in view of
previous reports (see Sladek et al., 1978)
that hepatic microsomal mixed-function
oxidase activity may be reduced in
animals with primary or transplanted
solid tumours.
Despite the marked decrease in MIS t,
after phenobarbitone or phenytoin, the
peak blood (or plasma) MIS concentra-
tions were reduced only slightly, if at all.
In contrast, the blood (or plasma) MIS
AUC was consistently decreased by 25-
6000'. The enhanced metabolism of MIS
caused by the enzvme inducers resulted in
an increased blood (or plasma) AUC for
the metabolite Ro 05-9963, amounting to
10-60% in BALB/c mice and 100% in the
BIO strain. Despite this increase, the blood
(or plasma) AUC for total 2-nitroimidazole
(MIS +Ro 05-9963) was always reduced
by 20-40% after enzyme induction.
XVe have shown that EMT6 tumour/
plasma ratios for both MIS and Ro 05-9963
were constant (within experiments) at
0-3-0-6. Values obtained for the MC6B
tumour were also constant, though higher
(- 0 7). For both tumours, we found that
the tumour/plasma ratios were not affected
when the MIS t, was shortened after
enzyme induction. This complements the
previous demonstration that this ratio
was unaltered when the t. for MIS
or injected Ro 05-9963 was prolonged
after kidney ligation (Brown et al.,
1979).
The brain/plasmaratiosforbothMIS and
Ro 05-9963 are also constant, and likewise
unaffected by the decreased MIS t, follow-
ing microsomal enzyme induction. For
MIS, tumour and brain concentrations
were very similar, except that the tumours
equilibrated less rapidly with the plasma
than did the brain. This may be due to
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poor tumour vascularization relative to
the high cerebral blood flow. In contrast
to MIS, concentrations of Ro 05-9963
were considerably lower in brain than
tumour. This is presumably related to the
fact that Ro 05-9963 is considerably less
lipophilic than MIS (Adams et al., 1976)
since lipophilicity is the major factor
affecting the penetration of unionized
compounds oflow molecular weight across
the blood-brain barrier (reviewed by
Bradbury & Davson, 1964). This would
suggest that if brain concentration con-
tributes to the neurotoxicity of nitro-
imidazoles (see below) Ro 05-9963 might
be less toxic than MIS. In mice, Ro 05-
9963 has a higher LD50 than MIS, and at
equal tumour concentrations they are
equally good radiosensitizers (Brown et
al., 1979). Ro 05-9963 therefore may have
potential for clinical use.
As for the peak plasma concentrations,
phenobarbitone and phenytoin did not
alter the peak MIS concentrations for
either tumour or brain. However, apparent
t, values for the elimination of MIS from
these tissues were shortened. Moreover,
the AUC for both MIS and total 2-nitro-
imidazole were reduced, although the
AUC for Ro 05-9963 was increased in some
experiments.
Having established that the pharmaco-
kinetics of MIS are indeed altered by
phenobarbitone and phenytoin the ques-
tion arises as to whether these interactions
alter the toxic and therapeutic effects of
MIS. Taking first the radiosensitization of
hypoxic cells by MIS, there is fairly good
evidence from animal experiments that
this property is a function of the concen-
tration of intact nitroimidazole in the
tumour at the time of radiation (McNally
et al., 1978). We have shown that the peak
tumour MIS concentration is not altered
by the enzyme inducers. Thus if radiation
is given at the time ofthe peak concentra-
tion, the radiosensitization should not be
affected. Of course, this presupposes that
pretreatment with the enzyme inducers
dose not have an adverse effect on the
radiation response involving mechanisms
24
unrelated to the effects on MIS disposition
kinetics.
For the present discussion it is con-
venient to consider 3 types oftoxicity dis-
played by MIS and related nitrohetero-
cyclics:
(1) Cytotoxicity. Nitroheterocyclics ex-
hibit cytotoxic properties with a
marked selectivity against hypoxic
cells (reviewed by Foster, 1978).
(2) Neurotoxicity. Peripheral neuro-
pathy is the dose-limiting toxicity
of MIS in man. (Dische et al., 1977;
Urtasun et al., 1978).
(3) Lethality. Acute LD50 assays in
mice are commonly used to assess
drug toxicity.
It is not clear what molecular species
may be responsible for these toxic effects.
Biotransformation may be involved, and
Fig. 7 summarizes the probable oxidative
and reductive reactions involved in the
Phase 1 metabolism of MIS in vivo. The
Phase 2 reactions, involving glutcuronide
conjugations, are unlikely to be ofinterest,
since the conjugates will be unable to
penetrate cell membranes and so are
rapidly excreted.
It appears that oxidative metabolism
has not been considered previously as con-
tributing to MIS toxicity. O-demethyla-
tion is catalysed by microsomal mixed-
function oxidases, proceeding via the inter-
mediate methylol which breaks down
spontaneously to the demethylated meta-
bolite and formaldehyde (Fig. 7A) (Parke,
1968). Previous studies with melamines,
such as hexamethylmelamine (HMMi) im-
plicated the N-methylols or formaldehyde
as possible toxic species (Rutty & Connors,
1977; Rutty et al., 1978). This is especially
pertinent as HMM also causes neuro-
toxicity in man. It is also relevant that the
hydroxymethyl metabolite of metronid-
azole is considerably more mutagenic than
the parent drug (Connor et al., 1977).
However, the selective cytotoxicity of
MIS against hypoxic cells apparently ex-
cludes oxidative metabolism from the
cytotoxic mechanism. Moreover, we have
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shown that when the brain and plasma
concentrations of the 0-demethylated
metabolite Ro 05-9963 are raised by
enzyme induction, the LD50 was actually
increased. This suggests that oxidative
metabolism is also not responsible for
MIS lethality. If death is due to neuro-
logical damage, this may likewise be true
for the neurotoxicity. The decreased body
temperature may involve a neurological
OXIDATIVE METABOLISM
N N-CH2CHCH20CH3
K~~~~~~~~~~~~
OH
NO2
I
OH
NO2
N N-CH2 CHCH20H
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I
NO2
+ HCHO
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N N-CH2
N02K_
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FiG. 7. Oxidative and redluctive metabolism of MIS.
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mechanism, and it is interesting that this
was more short-lived after enzyme in-
duction.
It is widely held that the selective cyto-
toxicity of nitroheterocyclics against
hypoxic cells implicates reductive metab-
olism in the cytotoxic mechanism (Ward-
man, 1977; Willson, 1977; Foster, 1978).
Reduiction of the nitro group to the amine
will proceed via the nitroradical anion,
nitroso, hydroxylamine and other poten-
tially cytotoxic intermediates (Fig. 7B)
(Wardman, 1977; Willson, 1.977; Whit-
more et al., 1978). The unstable amine has
beendetected in mouse tumours andhuman
urine (Flockhart et al., 1978a, b; Varghese
et al., 1976). Although nitroreduction is
probably responsible for MIS cytotoxicity,
its involvement in the neurotoxic and
lethal effects is unclear. It is, however,
pertinent to speculate on the possible
interactions of microsomal-enzyme in-
ducers.
T'reatment with microsomal-enzyme in-
ducers cauises increased concentrations of
cytochrome P-450, NADPH-cytochrome-c
reductase and phosphatidyl choline, which
together comprise the mixed-function
oxidase enzyme complex (Conney, 1967;
Lu & West, 1978). Cytochrome P-450 and
NADPH-cytochrome-c reductase catalyse
both oxidative and reductive reactions,
including the reduction of nitrohetero-
cyclics (Gillette, 1971, 1977). These latter
reactions are also carried out by soluble
enzymes, including aldehyde oxidase and
xanthine oxidase (Gillette, 1 971, 1 977)
and collectively these enzymes comprise
the tissue "nitroreductase".
Phenobarbitone pretreatment in vivo
increases nitroreduction by liver micro-
somes incubated under anoxic conditions
in vitro (Conney, 1967). However, this is
strongly inhibited by oxygen and may not
occur in well oxygenated normal tissues
in vivo (Gillette, 1971). Thus it is unlikely
that microsomal-enzyme inducers wvill
increase nitroreduction in normal tissues.
Infact, theincreased oxidative metabolism
is more likely to protect against any cyto-
toxicity op)erating via nit,roreduction.
Decreased nitroreduction may be a
factor involved in the increased MIS LD50
in mice pretreated with phenobarbitone
and phenytoin. However, two other possi-
bilities should be considered. Firstly, pre-
treatment with these agents may produce
a physiological tolerance to MIS unrelated
to metabolic factors. However, the in-
volvement of such an effect is normally
postulated only in cases where metabolic
factors cannot be implicated, whereas in
the present studies an increased oxidative
metabolism has been clearly demon-
strated. The second, and more likely,
possibility is that the AUC for MIS (or
total 2-nitroimidazole) may be responsible
for the lethal effect: in this case the in-
creased LD50 would be explained by the
decreased AUC. Likewise, the more rapid
clearance of MIS from the brain may
explain the quicker return to normal body
temperature.
There is some suggestion that the dose-
limiting neuropathy of MIS in man is
related to the AUC (Dische et al., 1977;
Saunders et al., 1978). If so, the toxicity
might be reduced by using micro-
somal enzyme inducers to decrease the
AUC.
It is certain that many cancer patients
receiving MIS will also require other
medications, including microsomal-enzyme
inducers. Phenobarbitone and phenytoin,
for example, are frequently administered
to brain-tumour patients. The present
studies provide pharmacological evidence
that the radiosensitization by MIS is
unlikely to be reduced by such induction
and, in addition, that the toxicity might
be decreased. Our preliminary studies in
man suggest that the MIS ti and AUC are
both reduced by phenytoin therapy.
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